XVIII International AIDS Conference, 2010 Vienna UNODC-GTZ satellite symposium:

OST saves lives – it's official! OST – a key to HIV prevention Opioid Substitution Treatment in Germany A Story of Success

Joerg Goelz Centre for HIV, Hepatitis and Addiction Medicine, Berlin

DGS – German Society of Addiction Medicine

Hans-Günter Meyer-Thompson

GTZ – German Technology Cooperation

### Harm Reduction in Germany

- Needle and syringe exchange by programmes and pharmacies
- Supervised Injection Facilities
- Opioid Substitution Treatment including
  psychosocial care
- Diamorphine Substitution Treatment
- Free access to HIV- and Hepatitis-Treatment
- Peer group counseling on safer use and safer sex
- OST in prisons (limited)

### **Rules for OST in Germany**

- Physicians with certificate (training of 50 hrs)
- Mandatory: psychosocial care
- Combined treatment of somatic and psychiatric diseases
- Dispensing in clinics, offices and pharmacies
- Urine analysis at regular intervals
- Detoxification of non prescribed drugs and substances and concomitant maintenance of OST
- Take-home-dosis after 6 months possible
- Stable life (housing, income, job rehabilitation)

#### Rules for Diamorphine (Heroin) Substitution Treatment


- Physicians with special training in DMT
- High security facilities
- Patients: > 23 years old and > 5 years of injecting heroin and failed MMT/BMT
- Concomitant somatic and/or psychiatric diseases
- 2 failed abstinence oriented therapies
- 6 months of psychosocial care mandatory

# Funding of opioid substitution treatment

- German Health Insurance System (doctors fee, psychiatric care, medication)
- Municipal Social Budgets
  (psychosocial care)
- German Federal Pension Fund (occupational rehabilitation, abstinence oriented treatment)

### Europe: Provision of OST by office-based GPs

Figure: Provision of opioid substitution treatment by office-based general practitioners (GPs)




The percentage of substitution treatment clients receiving their treatment from general practitioners in the community is indicated on the map Sources: Reitox national focal points (emcdda.europa.eu/about/partners/reitox-network).

Published by the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), Lisbon, Portugal, 2009.



# Germany:Specialisation of physicians providing OST



Total of 2 700 physicians + 500 physicians treating up to 3 IDU's under supervision


# Germany: Specialisation of physicians providing OST

- 85 % general practitioners (GPs)
  - 9% internists
  - 6 % psychiatrists

(Total of 2 600 OST practising physicians + 500 physicians treating up to 3 IDU's under supervision)

# Europe: Estimates of prevalence of IDU per 1000 population

Figure 1: Estimates of the prevalence of injecting drug use (cases per 1 000 population aged 15-64)




#### Substances to be used in Germany

Dihydrocodein (DHC)		since 1980
L-Methado <mark>ne</mark>		since 1985
D-/L-Methadone		since 1991
Buprenorphin		since 2000
LAAM	[	2000-2001
Diamorphine		since 2002
Buprenorphin + Naloxon		since 2007

Bundesinstitut für Arzneimittel und Medizinprodukte - Federal Institute for Drugs and Medical Devices




#### **Distribution of the opioids**




Bundesinstitut für Arzneimittel und Medizinprodukte - Federal Institute for Drugs and Medical Devices

#### Registered OST-patients in Germany 1990-2010




Bundesinstitut für Arzneimittel und Medizinprodukte - Federal Institute for Drugs and Medical Devices

### OST clients as percentage of the estimated problem opiod users




#### Europe: OST programmes in the community and the prison system 2007






### New HIV diagnosis in Germany by route of infection




Robert-Koch-Institut, Berlin, Epidemiologisches Bulletin, 7. Juni 2010 / Nr. 22


#### New HIV-infections among IDU's according to regions of origin



# HIV-prevalence among injecting drug users in Europe 2006/07



#### Reduction of death rate of IDU's in Germany



#### **Conclusions I**

- OST is integrated in the existing health care system
- Heroin substitution treatment needs public
  investments because of security requirements
- OST is covered by compulsory health insurance
- OST and HR is (by the majority) politically supported by federal and local parliaments, police superintendents, medical associations and PH administrations

#### **Conclusions II**

- 50% of all IDU's are in OST
- Majority of HIV-infected IDU's are in OST
- OST leads to a low rate of HIV-prevalence in IDU's
- OST leads to a very low incidence among IDU's
- OST reduces the rate of fatal overdoses
- OST is still limited in German prisons and in some rural regions
- OST works!